Bloomberg Intelligence Lilly Falls as Weight-Loss Pill Data Overshadows Sales Beat
7 snips
Aug 7, 2025 
Damian Garde, a Bloomberg News health reporter, dives into Eli Lilly's recent struggles as its new weight-loss pill disappoints, overshadowing a surge in its current obesity medication sales. He discusses the competitive landscape of weight-loss drugs and highlights the challenges of drug development. The conversation also touches on the broader impact on healthcare investments and the interplay between innovative treatments and market trends. Garde's insights paint a vivid picture of the fast-evolving pharmaceutical industry.
AI Snips
Chapters
Transcript
Episode notes
Lilly's Strong Cardiometabolic Revenue
- Cardiometabolic health products form 65% of Lilly's total revenue, excluding the new oral pill.
- Strong performance from existing obesity and diabetes drugs boosted Lilly's profit and sales outlook despite the new pill's trial setback.
Challenges of Oral Drug Development
- Developing effective oral versions of injectable drugs like GLP-1 is challenging due to safety and dosing issues.
- The high failure rate in drug development highlights the unpredictable nature of biology and medicine.
From Chemistry Lab to Space Shuttle
- Paul Sweeney shared what his freshman chemistry lab partner achieved: NFL wide receiver, scientist, and space shuttle astronaut.
- It illustrates extraordinary career trajectories and inspiration in science and technology.